Dr. James A Trovato is a pharmacist who is specialized in Oncology in Baltimore, Maryland. Patients can reach him at 10 N Greene St, Baltimore or contact him on 410-706-2751. Active license number of Dr. James A Trovato is 13732 for Oncology in Maryland. Dr. James A Trovato is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. James A Trovato speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. James A Trovato
Specialization:
Oncology
Credentials:
PHARM.D.
Gender:
Male
Location:
10 N Greene St, Baltimore, Maryland, 21201-1524
Phone:
410-706-2751
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. James A Trovato are as mentioned below.
NPI Number:
1700927118
NPI Enumeration Date:
09 Feb, 2007
NPI Last Update On:
04 Aug, 2009
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. James A Trovato are as mentioned below.
Specialization
License Number
State
Status
Oncology
13732
Maryland
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
20 N Pine St, Suite 448 Baltimore, Maryland
Zip:
21201-1142
Phone Number:
410-706-2751
Fax Number:
--
Patients can reach Dr. James A Trovato at 10 N Greene St, Baltimore, Maryland or can call on phone at 410-706-2751.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.